Viewpoint
The risk transfers at close. The visibility does not.
What food and beverage acquirers inherit, and when they find out.
In March, McCormick and Unilever announced a $44.8 billion combination of Unilever's food business. Ingredion agreed to buy Tate and Lyle. Those were the headline deals of the year so far.
The smaller ones are more revealing. Tilray, a Canadian company best known for cannabis, bought BrewDog's brand and its UK breweries. Gallo bought Four Roses, a Kentucky bourbon distillery, from its Japanese owner. Danone bought Huel, a British nutrition brand barely a decade old. Ferrero acquired Bold Snack, a premium protein snack manufacturer in Brazil.
Different sizes, different categories, different continents. One thing in common.
In every case the buyer has taken on products that are already on shelf, already making claims, already sold in markets the buyer may never have sold into, and already supplied by companies the buyer did not approve.
Capstone Partners found that 67.7% of branded acquisition targets in early 2026 carried positioning in better-for-you, high-protein, international or sustainability categories. That is the highest share since 2019.
In plain terms, established portfolios are buying brands that stand for something they cannot credibly say themselves. High protein. Low sugar. Naturally sourced. Free from.
Those are claims. Claims are the least stable thing a brand owns. They depend on rules that keep moving, on evidence that has to stay current, and on wording that is acceptable in one market and not in the next.
A large share of the value changing hands in this market is a permission to say something, in a particular place, at a particular moment.
The accountants establish what the business earns. The lawyers establish what it owes. Neither of them tells the buying company what it now has to keep true.
After the deal completes, the buyer owns all of the following.
|
What the buyer now owns |
What that means the morning after close |
|---|---|
|
Every claim on every pack |
Each one approved against the rules as they stood at the time, in a country that may have moved since, by people who now work for a different company or none at all. |
|
Labelling across a bigger footprint |
The brand's markets are rarely the same as the buyer's. New countries arrive with the deal, and each one brings its own labelling requirements to a team that has never had to hold them. |
|
A supplier base with its own specifications |
Ingredient origin, contaminant limits, packaging materials, allergen controls. Signed off against one company's standards and now sitting inside another. |
|
A supply chain the buyer has never walked |
A live network of suppliers, origins and sub-suppliers, each with its own hazard profile. Diligence checks that the certificates exist. It does not tell the buyer what is moving underneath them: a mycotoxin season in a new origin, a fraud pattern in an ingredient the buyer has never purchased, a supplier country whose export rules are changing. |
|
The growth story the deal was priced on |
Most acquisitions assume the brand goes into markets it does not currently reach. Whether it can is a market access question, and at signing it is often an assumption rather than a finding. |
The buyer's monitoring was tuned to the supply chain it built. It now owns one it did not.
See what your combined footprint actually looks like → Get in touch
The instinct is to call this a due diligence problem. Partly it is. But diligence is a short window with a deadline, run by outside advisers, and its job is to get the price right.
The harder stretch is the year or two after completion, when one regulatory and quality function becomes responsible for a business that may have doubled in size, using arrangements built for the smaller version of it.
What surfaces in the first year after completion
A claim that was safe where the brand grew up is not safe where the buyer sells. The brand did nothing wrong. It simply never sold there. Now it does, or the plan says it soon will.
A supplier specification approved under one set of rules sits outside another. Nobody changed anything. The footprint changed underneath the specification.
A rule that was still in draft during diligence publishes in the first year. The reformulation, the new artwork and the supplier conversation all needed to happen before that. The buyer did not know to have them.
A hazard emerges in an ingredient, or an origin, the buyer never sourced from. The acquired brand's supply chain has been running on its own risk radar, held by people who may have left with the deal. The buyer's food safety monitoring never covered these ingredients, these countries, these suppliers, because until close it did not need to. The gap is invisible until the first incident finds it.
"Understanding the risks inside a newly acquired asset is one of the hardest parts of the deal."
— One of Europe's most acquisitive food groups, speaking to Prodeen this year
None of these are failures of competence. They are what happens when a business gets bigger faster than the view over it does.
All of that is the defensive read, and it is only half the deal.
Nobody buys a brand to keep it exactly where it is. The plan is almost always to take it somewhere new. Danone did not buy Huel to sell it in Britain. A brand with a strong claim in one market is worth considerably more if that claim survives translation into five more.
Whether it does is not a marketing question. It is the same market access question, asked in the opposite direction.
Answer those and the expansion plan gets a sequence. The markets that are open now, the ones that need work and how much, and the ones that are not worth the effort yet. Most integration plans pick their order from commercial appetite and distribution readiness, then discover the regulatory position market by market as they go. That is an expensive way to find out, because the discovery usually arrives after the launch date has been committed.
It also works the other way round. An acquired brand sometimes turns out to be sellable somewhere nobody had considered, because its formulation and claims already sit inside a regime the parent company had written off years ago for a different product.
The inherited supply chain cuts the same way. An acquired supplier base is also an asset nobody priced. Suppliers already qualified against regimes the parent has been trying to enter. Origins that de-risk a concentration the parent has lived with for years. A protein source, a packaging format, a certification the parent's own brands could borrow. Most integrations treat the acquired supplier list as a cost-synergy exercise: consolidate, renegotiate, rationalise. Read as a market access asset instead, it sometimes answers a question the parent had stopped asking.
Market Access Intelligence is one living view of the rules, risks and trends that decide whether a product reaches a market and holds its place there. When a company has just bought another one, that means six things.
Just closed a deal, or about to? Get in touch.
Whether a portfolio was built or bought, the question is the same one, asked continuously.
Can I sell this product, in this market, with these claims, and through a supply chain someone else built?
For a business that has just doubled its portfolio, the difference is that the answer now has to hold for products it did not develop, in markets it has not sold into, on claims someone else stood behind.
Prodeen is the Market Access Intelligence platform. Speak to us about assessing an acquired portfolio across your combined footprint, and about sequencing where it can go next.
This piece draws on publicly announced food and beverage transactions and on published M&A market analysis. Deal values are as announced and are cited as indicative of a pattern rather than as a complete record of the market.